DexCom (NASDAQ:DXCM) PT Lowered to $100.00 at Citigroup

DexCom (NASDAQ:DXCMGet Rating) had its price objective cut by Citigroup from $105.00 to $100.00 in a report published on Friday morning, The Fly reports.

Other analysts have also recently issued research reports about the company. Canaccord Genuity Group cut their price objective on DexCom from $131.25 to $125.00 in a research note on Friday, April 29th. Raymond James cut their price objective on DexCom from $134.50 to $121.50 in a research note on Friday, April 29th. Morgan Stanley cut their price objective on DexCom to $90.75 and set an equal weight rating on the stock in a research note on Monday, June 13th. SVB Leerink cut their price objective on DexCom from $141.25 to $125.00 in a research note on Friday, April 29th. Finally, BTIG Research lowered their target price on DexCom from $135.00 to $105.00 and set a buy rating for the company in a report on Friday, June 24th. Two analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, DexCom presently has a consensus rating of Moderate Buy and a consensus price target of $115.23.

DexCom Trading Up 2.1 %

NASDAQ:DXCM opened at $83.83 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.30 and a current ratio of 4.72. DexCom has a one year low of $66.89 and a one year high of $164.86. The business’s 50-day simple moving average is $85.15 and its 200 day simple moving average is $98.90. The stock has a market cap of $32.90 billion, a price-to-earnings ratio of 174.65, a price-to-earnings-growth ratio of 3.28 and a beta of 1.03.

DexCom (NASDAQ:DXCMGet Rating) last released its quarterly earnings results on Thursday, July 28th. The medical device company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.02). DexCom had a return on equity of 11.79% and a net margin of 7.47%. The business had revenue of $696.20 million during the quarter, compared to analyst estimates of $709.33 million. During the same quarter last year, the firm posted $0.19 EPS. The company’s revenue was up 17.0% compared to the same quarter last year. As a group, sell-side analysts predict that DexCom will post 0.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Jereme M. Sylvain sold 600 shares of the stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $301.57, for a total value of $180,942.00. Following the completion of the transaction, the chief financial officer now directly owns 17,408 shares of the company’s stock, valued at approximately $5,249,730.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other DexCom news, Director Steven Robert Pacelli sold 1,000 shares of the business’s stock in a transaction dated Monday, July 25th. The shares were sold at an average price of $83.07, for a total value of $83,070.00. Following the sale, the director now directly owns 138,700 shares in the company, valued at $11,521,809. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Jereme M. Sylvain sold 600 shares of the business’s stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $301.57, for a total transaction of $180,942.00. Following the completion of the sale, the chief financial officer now owns 17,408 shares in the company, valued at $5,249,730.56. The disclosure for this sale can be found here. Insiders sold 3,627 shares of company stock valued at $676,977 in the last three months. 0.41% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On DexCom

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Lindbrook Capital LLC raised its position in DexCom by 321.2% in the second quarter. Lindbrook Capital LLC now owns 754 shares of the medical device company’s stock worth $56,000 after acquiring an additional 575 shares in the last quarter. Parallel Advisors LLC increased its stake in DexCom by 186.9% in the 2nd quarter. Parallel Advisors LLC now owns 1,684 shares of the medical device company’s stock worth $126,000 after purchasing an additional 1,097 shares in the last quarter. Empirical Finance LLC increased its stake in DexCom by 326.3% in the 2nd quarter. Empirical Finance LLC now owns 7,021 shares of the medical device company’s stock worth $523,000 after purchasing an additional 5,374 shares in the last quarter. US Bancorp DE increased its stake in DexCom by 271.6% in the 2nd quarter. US Bancorp DE now owns 97,036 shares of the medical device company’s stock worth $7,231,000 after purchasing an additional 70,924 shares in the last quarter. Finally, New York State Teachers Retirement System increased its stake in DexCom by 300.7% in the 2nd quarter. New York State Teachers Retirement System now owns 453,690 shares of the medical device company’s stock worth $33,814,000 after purchasing an additional 340,473 shares in the last quarter. 93.26% of the stock is currently owned by institutional investors.

DexCom Company Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Articles

The Fly logo

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Want More Great Investing Ideas?

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.